Satiasolv
Viral Infections
Pre-clinicalActive
Key Facts
About Marinomed Biotech
Marinomed Biotech is a publicly traded biopharmaceutical company developing therapies in virology and immunology based on its patented Marinosolv® technology platform. Its pipeline includes clinical-stage programs for allergic rhinitis and viral infections, alongside commercial-stage medical devices. The company faces near-term financial pressures, as evidenced by recent capital measures, and is exploring strategic options for its core platform while advancing its key clinical asset, Budesolv.
View full company profileTherapeutic Areas
Other Viral Infections Drugs
| Drug | Company | Phase |
|---|---|---|
| Haptenized Viral Vaccines | BioVaxys | Preclinical |
| Cell-based Antiviral Drug Discovery Platform | Lucerna | Development |
| XAV19 | Xenothera | Preclinical |
| Antiviral Screening Services | NeoVirTech | Pre-clinical |
| Anti-Viral Program | MicroQuin | Pre-clinical |
| Telomir-1 | Telomir Pharmaceuticals | Pre-clinical |
| DehydraTECH for Antivirals | Lexaria Bioscience | Preclinical |
| RECCE® 529 | Recce Pharmaceuticals | Preclinical |